Pictet Asset Management (Switzerland)’s Akero Therapeutics AKRO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$53.4M	Buy	+1,144,082	New	+$52.4M	0.06%	281

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s AKRO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) opened a new position in Akero Therapeutics (AKRO) in Q2 2023: 1,144,082 shares worth $53.4M. The stake represents 0.06% of the portfolio and ranks #281 among its holdings.

157 funds tracked by Wall St. Rank hold AKRO as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,144,082 shares of Akero Therapeutics worth $53.4M as of Q2 2023.
Akero Therapeutics was a new Pictet Asset Management (Switzerland) position in Q2 2023.
Akero Therapeutics made up 0.06% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #281 holding.
157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.